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The pineal secretory product melatonin (chemically, N-acetyl-5-methoxytryptamine) acts as an eﬀective antioxidant and free-
radical scavenger and plays an important role in several physiological functions such as sleep induction, immunomodulation,
cardiovascular protection, thermoregulation, neuroprotection, tumor-suppression and oncostasis. Membrane lipid-peroxidation
in terms of malondialdehyde (MDA) and intracellular glutathione (GSH) is considered to be a reliable marker of oxidative stress.
ThepresentworkwasundertakentostudythemodulatingeﬀectofmelatoninonMDAandGSHinhumanerythrocytesduringday
and night. Our observation shows the modulation of these two biomarkers by melatonin, and this may have important therapeutic
implications.In vitro dose-dependent eﬀect ofmelatoninalsoshowedvariationduringdayandnight.Weexplainourobservations
on the basis of melatonin’s antioxidative function and its eﬀect on the ﬂuidity of plasma membrane of red blood cells. Rhythmic
modulationofMDAandGSHcontentsemphasizedtheroleofmelatoninasanantioxidantanditsfunctionagainstoxidativestress.
1.Introduction
Oxidative stress, or the imbalance between oxidant pro-
duction and antioxidant levels, appears to be favour of the
former, consequently resulting in acceleration of neurode-
generation, cognitive impairment, immunosuppression, and
ageing [1]. Melatonin (N-acetyl-5-methoxytryptamine) has
been known for a long time as the major hormone produced
by the pineal gland, but later, it has emerged as a compound
that can also be synthesized in other organs and tissues and
serves as an autacoid factor. Pineal melatonin is involved in
manyphysiologicalfunctions,amongthemsleeppromotion,
circadian regulation, immunomodulation, neuroprotection,
and tumour suppression. This pineal indoleamine exhibits
characteristic diurnal rhythm of synthesis and secretion,
which attains its peak at night followed by a gradual decrease
during the daytime. In addition, pharmacological doses
of melatonin eﬀectively reduce oxidative stress through a
number of mechanisms [2].
Melatonin scavenges hydrochlorous acid, detoxiﬁes hig-
hly toxic hydroxyl and peroxyl radicals in vitro and scav-
enges peroxynitrite. It has also been reported to increase
the synthesis of glutathione and of several antioxidant
enzymes [3]. Upon metabolism, melatonin converts to a
number of antioxidant compounds such as, N1-acetyl-N2-
formyl-5-methoxy-kynuramine and N1-acetyl-5-methoxy-
kynuramine [4]. Therefore, melatonin is considered to be
a broad-spectrum antioxidant. It was found to be more
powerful than glutathione and mannitol in neutralizing free
radicals and can protect cell membranes from oxidative
damage more eﬀectively than vitamin E [1, 5].
The present study was undertaken to understand the
modulation of intracellular reduced glutathione (GSH) and
malondialdehyde (MDA) by melatonin in human red blood
cells according to the oscillatory circadian changes in levels
of this hormone. We have also studied the dose-dependent
eﬀect of melatonin on GSH and MDA in erythrocytes
obtained from blood at two diﬀerent times, subjected to
oxidative stress by incubating with tert-butyl hydroperoxide
(t-BHP) [6]. We used t-BHP as pro-oxidant, because it
does not undergo degradation by the cytosolic catalase [7].
Thus, the possibility of its pro-oxidative activity getting
hampered by the catalase upregulation by melatonin is
minimised.2 International Journal of Cell Biology
2.MaterialandMethods
T h es t u d yw a sc a r r i e do u to nd i ﬀerent healthy donors of
both sexes who gave informed consent for the use of their
blood samples for the study. The criteria for screening of
volunteersincludednonsmokingindividualshavingnoacute
or chronic diseases (such as diabetes mellitus, asthma, or
tuberculosis) or organ dysfunction and had not taken any
medication [8, 9]. The protocol of study was in conformity
with the guidelines of the Institutional Ethical Committee.
Bloodsampleswerecollectedbyvenipunctureinheparinised
vials (10IU/mL) at two diﬀerent timings of the day, namely,
10:00hrs.(attheoﬀsetofmelatoninsecretion)and22:00hrs.
(at the onset of melatonin secretion). The red blood cells
(RBCs) were sedimented at 1800g for 10min at 4◦Ca n d
washed three times with cold phosphate-buﬀered saline, pH
7.4containing0.154mMNaCland10mMNa2HPO4.Super -
natantandbuﬀycoatwerecarefullyremovedaftereachwash.
2.1. Determination of MDA Content. Erythrocyte MDA was
measured according to the method of Esterbauer and
Cheeseman with slight modiﬁcation [10]. Packed erythro-
cytes (0.2mL) were suspended in 3.0mL PBS containing
0.5mM glucose. The lysate (0.2mL) was added to 1.0mL of
10% trichloroacetic acid and 2.0mL of 0.67% thiobarbituric
acid, boiled for 20 minutes at temperature >90◦C, cooled,
and the absorbance read at 532nm. Concentration of MDA
is calculated using extinction coeﬃcient (ε = 31,500) and is
expressed as nmol·mL−1 of packed erythrocytes.
2.2. Determination of GSH Content. Erythrocyte GSH was
measured following the method of Beutler [11]. The method
was based on the ability of the –SH group to reduce 5,5 -
dithiobis,2-nitrobenzoic acid (DTNB) and form a yellow
coloured anionic product whose OD is measured at 412nm.
ConcentrationofGSHisexpressedinmilligrampermillilitre
packed RBCs and was determined from standard plot.
2.3. Induction of Oxidative Stress and In Vitro Eﬀect of
Melatonin. Blood was washed two to three times with PBS
containing 5mM glucose (GPBS), pH 7.4. Erythrocytes were
then suspended in 4 volumes of GPBS. A stock solution
(10mM) of melatonin was prepared in absolute ethanol;
further dilutions (10−4 M–10−8 M) were done with PBS. The
concentrationofethanolwasalways<0.01%(v/v)intheﬁnal
solution. The in vitro eﬀect of melatonin was evaluated by
incubating erythrocytes with melatonin at diﬀerent doses
(10−5 M–10−9 M ﬁnal concentration) of melatonin for 30
minutes at 37◦C. The erythrocytes were again washed two
to three times with PBS, pH 7.4, to remove any amount of
thecompound,andﬁnally,packederythrocyteswereusedfor
the assay of MDA and GSH. In parallel control experiments,
blood was incubated with ethanol (ﬁnal concentration not
more than 0.01% (v/v)) but without melatonin.
Oxidative stress was induced in vitro by incubat-
ing washed erythrocytes with tert-Butyl hydroperoxide
(10−5 mol·L−1 ﬁnal concentration) in presence and absence


















Figure 1: Day and night variation in malondialdehyde content in
red blood cells. Signiﬁcant decrease was observed in level of MDA
in nocturnal samples (∗P<. 05). MDA content is expressed as
nanomoles per millilitres of packed RBCs.
t-BHP used in the present study to induce oxidative stress of
erythrocytes was in the range of concentrations used in other
published reports [12].
3. Result andDiscussion
The current study was designed to determine whether circa-
dian rhythm-associated variations in the levels of malondi-
aldehydeandglutathioneoccurintheerythrocytesofhealthy
adults and to investigate the concentration-dependent eﬀect
of melatonin on variation in these two biomarkers of
oxidative stress. Malondialdehyde and hydroxynonenal, by-
productsoflipidperoxidation,areconsideredastoxicsecond
messengers that can diﬀuse within or even escape from the
cell and attack targets far from the site of production. MDA
is considered to be one of the reliable markers of cellular
peroxidative damage.
Figure 1 shows a signiﬁcant (P<. 05) variation in
erythrocyte MDA content in the blood samples collected
during night and in the morning. Such a rhythmic vari-
ation in MDA is indicative of the relationship between
oxidative stress and periodic changes in melatonin synthesis
in response to photic and nonphotic signals. The dose-
dependent eﬀect of melatonin on erythrocyte MDA content
after in vitro oxidative insult by incubating with t-BHP
is shown in Figure 2. Incubation with t-BHP caused a
signiﬁcantincreaseinMDAcontentinerythrocytesobtained
during day and night. A high dose of melatonin (10−4 M)
resulted in a signiﬁcant decrease in MDA content (P<
.05), and lower concentrations of melatonin showed slightly
greater protection of lipid peroxidation. It was observed
that the physiological level (10−9 M) of melatonin exerted
maximum protective eﬀect. The eﬀect of melatonin may be






































































Figure 2: Day and night variation in malondialdehyde content
in red blood cells after in vitro treatment with melatonin. The
points () and ()r e p r e s e n tt h ee ﬀect of melatonin in diurnal
and nocturnal blood samples, respectively. Signiﬁcant variation was
observed in diurnal-treated samples (∗P<. 05), the response being
pronounced at nanomolar doses. MDA content is expressed as



















Figure 3: Day and night variation in intracellular reduced glu-
tathione (GSH) content in red blood cells. Signiﬁcant increase was
observed in level of GSH in the diurnal samples (∗P<. 05). GSH
c o n t e n ti se x p r e s s e da sm i l l i g r a mp e rm i l l i l i t r ep a c k e dR B C s .
Glutathione, an eﬃcient antioxidant present in almost
all living cells, is also considered as a biomarker of redox
imbalance at cellular level. Figure 3 shows marked increase
in erythrocyte GSH content in nocturnal samples which
highlights the role of endogenous melatonin in the circadian







































































Figure 4: Day and night variation in reduced glutathione (GSH)
content in red blood cells after in vitro treatment with melatonin.
The points () and ()r e p r e s e n tt h ee ﬀect of melatonin in
diurnal and nocturnal blood samplesr e s p e c t i v e l y .D o s e - d e p e n d e n t
variation was observed in both diurnal and nocturnal samples in
response to in vitro treatment. Signiﬁcant change was observed at
10−9 M concentration of melatonin (∗P<. 05). GSH content is
expressed as milligram per millilitre packed RBCs.
increase in erythrocyte GSH content in the presence of
m e l a t o n i nc a nb es e e ni nFigure 4. Exogenous melatonin
demonstrated a protective eﬀect against t-BHP-induced
peroxidative damage in both diurnal and nocturnal samples,
the eﬀect being more pronounced at nanomolar doses.
Melatonin was found to inhibit GSH oxidation in a dose-
dependent manner; the antioxidative function of exogenous
melatonin bears close proximity to peak physiological level
of this indole neurohormone.
Oxidative free radicals resulting from cellular meta-
bolism tend to disturb cellular membrane integrity and
enzyme activities in red blood cells. Free radical-induced
lipid peroxidation intensiﬁes in the absence of a protective
antioxidant defence mechanism resulting in decrease in
cell membrane ﬂuidity. Under physiological conditions, the
reactive oxygen species are eliminated by enzymatic and
nonenzymatic antioxidant defence systems. Knowledge of
the absorption and metabolism of exogenous indoleamine
drugbecomesessentialbeforeanyconclusionsmaybedrawn
regarding its potential to exert biological activity in vivo,a s
suggested by in vitro studies. Melatonin owes its free radical-
scavenging property to the methoxy group at position-5 of
the indole nucleus and the acetyl group of the side chain of
melatonin [13].
The low concentration of MDA in nocturnal samples
is in conformity with previous reports that proposed the
periodicity in lipid peroxidation alongwith circadian rhyth-
micity [14]. Melatonin has been demonstrated to curb the
cytotoxic eﬀects induced by MDA [15]. Also, melatonin
administration reduces lipid peroxidation in mammalian
cells [16]. The eﬀect of melatonin in combating the perox-
idative degeneration was found to be more pronounced at4 International Journal of Cell Biology
a concentration close to nanomolar dose which may be
underlying the earlier studies showing the nocturnal drop in
cellular MDA content. The nocturnal blood samples, how-
ever, show no signiﬁcant response to in vitro indoleamine
treatment indicating suppressed activity of exogenous mela-
tonin in presence of the endogenous hormone.
The observed decrease of lipid peroxidation cannot be
explained merely on the basis of the direct scavenging
of lipoperoxyl radicals by melatonin. The less eﬀect of
melatonin at a still higher concentration (10−5 M-10−6 M)
may be attributed to the fact that the indoleamine is a
weak lipoperoxyl radical scavenger and is least eﬀective
in counteracting the accumulation of lipid peroxides in
the membrane of RBCs under induced oxidative chal-
lenge [17, 18]. Zavodnik et al. [19] reported inhibition
of membrane lipid peroxidation in human erythrocytes
treated with organic hydroperoxide as well as reduced
radical-induced generation of luminal-dependent chemilu-
minescence after in vitro treatment with melatonin. Drug
potency of melatonin at higher doses is quite evident
from previous reports [20]. The protection of lipids by
melatonin can also be explained as that of a preventive
antioxidant in our system. The suppression of erythrocyte
membrane lipid peroxidation by melatonin has prompted
the suggestion for the use of melatonin for preventive
and therapeutic purposes during cardiopulmonary bypass
surgery [21].
The recycling of glutathione in the cells depends on
an NADPH-dependent glutathione enzyme system which
includes glutathione peroxidise, glutathione reductase, and
γ-glutamyl-cysteine synthase forming a meshwork of an
antioxidative system. Melatonin has been found to upreg-
ulate cellular glutathione level to check lipid peroxidation
in brain cells [22]. The stimulatory eﬀect of melatonin on
the regulation of the antioxidant enzymes has been reported
[23]. Since melatonin has an amphiphilic nature, its antiox-
idative beneﬁt reaches the red blood cells, transcending
the membrane barriers in a nonreceptor-mediated mech-
anism. Melatonin’s antioxidative implications also extend
to the upregulation of some antioxidant enzymes directly.
Glutathione reductase and glutathione peroxidase, major
constituents of the glutathione-redox system, are reportedly
stimulated by melatonin [24]. The plasma GSH/GSSG redox
state is controlled by multiple processes, which includes
synthesis of GSH from its constitutive amino acids, cyclic
oxidation and reduction involving GSH peroxidase and
GSSG reductase, transport of GSH into the plasma, and the
degradation of GSH and GSSG by γ-glutamyltranspeptidase.
The increase in erythrocyte GSH concentration after mela-
tonin administration could be linked to the known stimula-
tion of γ-glutamylcysteine synthase, a rate-limiting enzyme
in reduced glutathione synthesis, by melatonin [25]. The
stimulation of GSH synthesis by melatonin is a major
antioxidative action of melatonin. Experimental evidences
are supportive of the circadian variation of cellular GSH
levels [26]. The increase in the GSH level with exogenous
melatonin in a concentration-dependent manner observed
in our experiment signiﬁes the eﬃcacy of this indole
compound close to normal physiological level.
4. Conclusion
Melatonin, due to its circadian secretion, causes day and nig-
ht modulation in the markers of oxidative stress. Erythrocyte
M D Aa n dG S Hc o n t e n t sa r ea ﬀected by melatonin according
to the changes in photic signals, which emphasizes the role
of melatonin as an antioxidant and its function against oxi-
dative stress in red blood cells. The eﬀect of exogenous mela-
tonin has been related to plasma-membrane ﬂuidity as well
as its free radical-scavenging potential. In addition, exoge-
nous melatonin has eﬀects on these antioxidant-defence
systemswhichmayhaveimportanttherapeuticimplications.
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